Mineralocorticoid Receptor Antagonists

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 28 Oct 2019Publisher:International Cardiovascular Forum JournalJournal:International Cardiovascular Forum Journal, volume 17 (issn: 2410-2636, eissn: 2409-3424,

Copyright policy )

Authors: Ilaria Spoletini; Giuseppe Rosano;

doi: 10.17987/icfj.v17i0.603

Mineralocorticoid Receptor Antagonists

- Summary
- Metrics

Abstract

The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is well-recognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to reduce mortality in HFrEF. In patients with HFpEF, the TOPCAT trial found no significant benefits of spironolactone on cardiovascular outcomes. In order to overcome the limitations of existing steroidal MRAs, novel MRAs have been recently developed, finerenone and PF-03882845.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average